Clinical trial NCT03451279 - References

Nonalcoholic Steatohepatitis (NASH) — A Nonabsorbable Ileal Apical Sodium-Dependent Bile Acid Transporter Inhibitor for Nonalcoholic Steatohepatitis

Citation(s)

•   Abu-Shanab A, Quigley EM
  The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010 Dec;7(12):691-701. doi: 10.1038/nrgastro.2010.172. Epub 2010 Nov 2. Review.
•   Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P
  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005 Jul;129(1):113-21.
•   Adorini L, Pruzanski M, Shapiro D
  Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012 Sep;17(17-18):988-97. doi: 10.1016/j.drudis.2012.05.012. Epub 2012 May 29. Review.
•   Alisi A, Ceccarelli S, Panera N, Nobili V
  Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol. 2012 Oct 26;2:132. doi: 10.3389/fcimb.2012.00132. eCollection 2012.
•   Alkhouri N, McCullough A
  Obesity, Inflammation, Nonalcoholic Fatty Liver Disease, and Hepatocellular Carcinoma. In: Obesity. New York, NY: Springer New York; 2013:219-234.
•   Anstee QM, Targher G, Day CP
  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44. doi: 10.1038/nrgastro.2013.41. Epub 2013 Mar 19. Review.
•   Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K
  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006 Nov 30;355(22):2297-307.
•   Bourzac K
  Microbiome: the bacterial tightrope. Nature. 2014 Dec 4;516(7529):S14-6. doi: 10.1038/516S14a.
•   Braun A, Yesilaltay A, Acton S, Broschat KO, Krul ES, Napawan N, Stagliano N, Krieger M
  Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Atherosclerosis. 2008 May;198(1):77-84. Epub 2007 Dec 3.
•   Brenner C, Galluzzi L, Kepp O, Kroemer G
  Decoding cell death signals in liver inflammation. J Hepatol. 2013 Sep;59(3):583-94. doi: 10.1016/j.jhep.2013.03.033. Epub 2013 Apr 6. Review.
•   Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH
  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004 Dec;40(6):1387-95.
•   Brunt EM
  What's in a NAme? Hepatology. 2009 Sep;50(3):663-7. doi: 10.1002/hep.23070.
•   Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH
  Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S51-60. Review.
•   Dawson PA, Karpen SJ
  Intestinal transport and metabolism of bile acids. J Lipid Res. 2015 Jun;56(6):1085-99. doi: 10.1194/jlr.R054114. Epub 2014 Sep 10. Review.
•   Dawson PA, Lan T, Rao A
  Bile acid transporters. J Lipid Res. 2009 Dec;50(12):2340-57. doi: 10.1194/jlr.R900012-JLR200. Epub 2009 Jun 4. Review.
•   de Aguiar Vallim TQ, Tarling EJ, Edwards PA
  Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013 May 7;17(5):657-69. doi: 10.1016/j.cmet.2013.03.013. Epub 2013 Apr 18. Review.
•   De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, Mingarelli E, Facinelli B, Magi G, Palmieri C, Marzioni M, Benedetti A, Svegliati-Baroni G
  Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014 May;59(5):1738-49. doi: 10.1002/hep.26695. Epub 2014 Feb 25.
•   Dumas ME, Kinross J, Nicholson JK
  Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology. 2014 Jan;146(1):46-62. doi: 10.1053/j.gastro.2013.11.001. Epub 2013 Nov 7.
•   Duseja A, Chawla YK
  Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis. 2014 Feb;18(1):59-71. doi: 10.1016/j.cld.2013.09.002. Epub 2013 Oct 24. Review.
•   Duwaerts CC, Maher JJ
  Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis. Curr Hepatol Rep. 2014 Jun 1;13(2):119-129.
•   Farrell G
  Should we lower lipids in nonalcoholic fatty liver disease? Clin Gastroenterol Hepatol. 2014 Jan;12(1):152-5. doi: 10.1016/j.cgh.2013.07.041. Epub 2013 Aug 16. Review.
•   Farrell GC, van Rooyen D
  Liver cholesterol: is it playing possum in NASH? Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G9-11. doi: 10.1152/ajpgi.00008.2012. Epub 2012 May 3.
•   Groen AK, Bloks VW, Verkade H, Kuipers F
  Cross-talk between liver and intestine in control of cholesterol and energy homeostasis. Mol Aspects Med. 2014 Jun;37:77-88. doi: 10.1016/j.mam.2014.02.001. Epub 2014 Feb 18. Review.
•   Harach T, Pols TW, Nomura M, Maida A, Watanabe M, Auwerx J, Schoonjans K
  TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep. 2012;2:430. doi: 10.1038/srep00430. Epub 2012 May 30.
•   Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA
  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012 Feb 1;482(7384):179-85. doi: 10.1038/nature10809.
•   Henkel A, Green RM
  The unfolded protein response in fatty liver disease. Semin Liver Dis. 2013 Nov;33(4):321-9. doi: 10.1055/s-0033-1358522. Epub 2013 Nov 12. Review.
•   Lade A, Noon LA, Friedman SL
  Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol. 2014 Jan;26(1):100-7. doi: 10.1097/CCO.0000000000000042. Review.
•   Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM
  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013 Jul 1;178(1):38-45. doi: 10.1093/aje/kws448. Epub 2013 May 23.
•   Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, Perlemuter G, Cassard-Doulcier AM, Gérard P
  Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013 Dec;62(12):1787-94. doi: 10.1136/gutjnl-2012-303816. Epub 2012 Nov 29.
•   Le TA, Chen J, Changchien C, Peterson MR, Kono Y, Patton H, Cohen BL, Brenner D, Sirlin C, Loomba R; San Diego Integrated NAFLD Research Consortium (SINC)
  Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology. 2012 Sep;56(3):922-32. doi: 10.1002/hep.25731. Epub 2012 Jul 2.
•   Li T, Chiang JY
  Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014 Oct;66(4):948-83. doi: 10.1124/pr.113.008201. Review.
•   Loomba R, Sanyal AJ
  The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90. doi: 10.1038/nrgastro.2013.171. Epub 2013 Sep 17. Review.
•   Luedde T, Kaplowitz N, Schwabe RF
  Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014 Oct;147(4):765-783.e4. doi: 10.1053/j.gastro.2014.07.018. Epub 2014 Jul 18. Review.
•   Mells JE, Anania FA
  The role of gastrointestinal hormones in hepatic lipid metabolism. Semin Liver Dis. 2013 Nov;33(4):343-57. doi: 10.1055/s-0033-1358527. Epub 2013 Nov 12. Review.
•   Michelotti GA, Machado MV, Diehl AM
  NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):656-65. doi: 10.1038/nrgastro.2013.183. Epub 2013 Oct 1. Review.
•   Mitchel EB, Lavine JE
  Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014 Nov;40(10):1155-70. doi: 10.1111/apt.12972. Epub 2014 Sep 29. Review.
•   Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, May SB, Kramer JR, Richardson PA, Davila JA
  Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015 Mar;13(3):594-601.e1. doi: 10.1016/j.cgh.2014.08.013. Epub 2014 Aug 19.
•   Morelli A, Vignozzi L, Maggi M, Adorini L
  Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. Biochim Biophys Acta. 2011 Aug;1812(8):859-66. doi: 10.1016/j.bbadis.2010.10.013. Epub 2010 Nov 5. Review.
•   Moschen AR, Kaser S, Tilg H
  Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab. 2013 Nov;24(11):537-45. doi: 10.1016/j.tem.2013.05.009. Epub 2013 Jul 1. Review.
•   Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, Zhong Z, Valasek MA, Seki E, Hidalgo J, Koike K, Kaufman RJ, Karin M
  ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell. 2014 Sep 8;26(3):331-343. doi: 10.1016/j.ccr.2014.07.001. Epub 2014 Aug 14.
•   Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A
  From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013 Oct;59(4):859-71. doi: 10.1016/j.jhep.2013.05.044. Epub 2013 Jun 7. Review.
•   Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network
  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7. Erratum in: Lancet. 2015 Mar 14;385(9972):946. Lancet. 2016 Apr 16;387(10028):1618.
•   Neuschwander-Tetri BA
  Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010 Aug;52(2):774-88. doi: 10.1002/hep.23719. Review.
•   Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM
  Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005 Mar;15(3):310-5.
•   Pearlman M, Loomba R
  State of the art: treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2014 May;30(3):223-37. doi: 10.1097/MOG.0000000000000060. Review.
•   Pols TW
  TGR5 in inflammation and cardiovascular disease. Biochem Soc Trans. 2014 Apr;42(2):244-9. doi: 10.1042/BST20130279. Review.
•   Potthoff MJ, Potts A, He T, Duarte JA, Taussig R, Mangelsdorf DJ, Kliewer SA, Burgess SC
  Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol. 2013 Feb 15;304(4):G371-80. doi: 10.1152/ajpgi.00400.2012. Epub 2012 Dec 20.
•   Prawitt J, Caron S, Staels B
  Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. Trends Endocrinol Metab. 2014 May;25(5):235-44. doi: 10.1016/j.tem.2014.03.007. Epub 2014 Apr 11. Review.
•   Quintero P, Pizarro M, Solís N, Arab JP, Padilla O, Riquelme A, Arrese M
  Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. J Physiol Biochem. 2014 Sep;70(3):667-74. doi: 10.1007/s13105-014-0336-1. Epub 2014 May 10.
•   Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T; LIDO Study Group
  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008 Jul;135(1):100-10. doi: 10.1053/j.gastro.2008.03.078. Epub 2008 Apr 8.
•   Ratziu V, Pienar L
  Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones? Hepatol Res. 2011 Jul;41(7):687-95. doi: 10.1111/j.1872-034X.2011.00825.x.
•   Ratziu V
  Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):676-85. doi: 10.1038/nrgastro.2013.193. Epub 2013 Oct 15. Review.
•   Ratziu V
  Starting the battle to control non-alcoholic steatohepatitis. Lancet. 2015 Mar 14;385(9972):922-4. doi: 10.1016/S0140-6736(14)62010-9. Epub 2014 Nov 7.
•   Ray K
  NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more? Nat Rev Gastroenterol Hepatol. 2015 Jan;12(1):1. doi: 10.1038/nrgastro.2014.203. Epub 2014 Nov 25.
•   Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN
  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28.
•   Schaap FG, Trauner M, Jansen PL
  Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014 Jan;11(1):55-67. doi: 10.1038/nrgastro.2013.151. Epub 2013 Aug 27. Review.
•   Schnabl B, Brenner DA
  Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014 May;146(6):1513-24. doi: 10.1053/j.gastro.2014.01.020. Epub 2014 Jan 15. Review.
•   Schwabe RF, Maher JJ
  Lipids in liver disease: looking beyond steatosis. Gastroenterology. 2012 Jan;142(1):8-11. doi: 10.1053/j.gastro.2011.11.004. Epub 2011 Nov 19.
•   Seki E, Schnabl B
  Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012 Feb 1;590(3):447-58. doi: 10.1113/jphysiol.2011.219691. Epub 2011 Nov 28. Review.
•   Seki E
  Microbiome-obesity-liver cancer interaction: senescence of hepatic stellate cells and bile acids play new roles. Gastroenterology. 2014 Mar;146(3):860-1. doi: 10.1053/j.gastro.2014.01.029. Epub 2014 Jan 24.
•   Solís N, Pizarro M, Quintero P, Arab JP, Riquelme A, Padilla O, Carrasco G, Pirola CJ, Sookoian S, Arrese M
  Effects of bile acid sequestration on hepatic steatosis in obese mice. Ann Hepatol. 2013 Jan-2014 Feb;13(1):105-12.
•   Sonne DP, Hansen M, Knop FK
  Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. Eur J Endocrinol. 2014 Aug;171(2):R47-65. doi: 10.1530/EJE-14-0154. Epub 2014 Apr 23. Review.
•   Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, Baron M, Lucas A, Tailleux A, Hum DW, Ratziu V, Cariou B, Hanf R
  Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013 Dec;58(6):1941-52. doi: 10.1002/hep.26461. Epub 2013 Oct 29.
•   Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL
  Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E462-8. Epub 2004 Aug 31.
•   Tomita K, Teratani T, Suzuki T, Shimizu M, Sato H, Narimatsu K, Okada Y, Kurihara C, Irie R, Yokoyama H, Shimamura K, Usui S, Ebinuma H, Saito H, Watanabe C, Komoto S, Kawaguchi A, Nagao S, Sugiyama K, Hokari R, Kanai T, Miura S, Hibi T
  Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology. 2014 Jan;59(1):154-69. doi: 10.1002/hep.26604. Epub 2013 Nov 18.
•   Tremont SJ, Lee LF, Huang HC, Keller BT, Banerjee SC, Both SR, Carpenter AJ, Wang CC, Garland DJ, Huang W, Jones C, Koeller KJ, Kolodziej SA, Li J, Manning RE, Mahoney MW, Miller RE, Mischke DA, Rath NP, Fletcher T, Reinhard EJ, Tollefson MB, Vernier WF, Wagner GM, Rapp SR, Beaudry J, Glenn K, Regina K, Schuh JR, Smith ME, Trivedi JS, Reitz DB
  Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1). J Med Chem. 2005 Sep 8;48(18):5837-52.
•   Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, Teoh NC, Farrell GC
  Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology. 2011 Oct;141(4):1393-403, 1403.e1-5. doi: 10.1053/j.gastro.2011.06.040. Epub 2011 Jun 23.
•   Videla LA, Pettinelli P
  Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity. PPAR Res. 2012;2012:107434. doi: 10.1155/2012/107434. Epub 2012 Dec 9.
•   Wanless IR, Lentz JS
  Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990 Nov;12(5):1106-10.
•   Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA
  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011 Jan;140(1):124-31. doi: 10.1053/j.gastro.2010.09.038. Epub 2010 Sep 19.
•   Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE
  From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):627-36. doi: 10.1038/nrgastro.2013.149. Epub 2013 Aug 20. Review.
•   Yeh MM, Brunt EM
  Pathological features of fatty liver disease. Gastroenterology. 2014 Oct;147(4):754-64. doi: 10.1053/j.gastro.2014.07.056. Epub 2014 Aug 7. Review.
•   Yilmaz Y, Younossi ZM
  Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014 Feb;18(1):19-31. doi: 10.1016/j.cld.2013.09.018. Epub 2013 Oct 24. Review.
•   Zarrinpar A, Loomba R
  Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012 Nov;36(10):909-21. doi: 10.1111/apt.12084. Epub 2012 Oct 11. Review.
•   Zheng X, Ekins S, Raufman JP, Polli JE
  Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm. 2009 Sep-Oct;6(5):1591-603. doi: 10.1021/mp900163d.
•   Zhou H, Hylemon PB
  Bile acids are nutrient signaling hormones. Steroids. 2014 Aug;86:62-8. doi: 10.1016/j.steroids.2014.04.016. Epub 2014 May 10. Review.

Use of A4250, a Nonabsorbable Ileal Apical Sodium-Dependent Bile Acid Transporter Inhibitor for Nonalcoholic Steatohepatitis (BRAVO-1)

Details for clinical trial NCT03451279